New report shows over 500 neurological meds in development by US firms

Neurological disorders, which include more than 1,000 conditions that disrupt the brain and nervous system, affect an estimated 100 million Americans, nearly one third of the US population.

According to a recent study, this number is likely to increase, as the number of Americans ages 65 and over in the USA is projected to nearly double, noted Andrew Powaleny, director of public affairs at Pharmaceutical and Research manufacturers of America in a PhRMA posting.

With the annual cost of neurological disorders already approaching $800 billion, new treatments that both modify and prevent neurological disease are more critical than ever. Today, a new report shows there are currently 537 medicines in development for numerous, wide-ranging neurological disorders by America’s biopharmaceutical companies. These include 95 medicines for brain tumors, 92 for Alzheimer’s disease, 46 for chronic pain and many more impacting conditions ranging from multiple sclerosis to amyotrophic lateral sclerosis (ALS).